NCT04052113View on ClinicalTrials.gov

Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer

CompletedOBSERVATIONAL
Enrollment

152

Participants

Timeline

Start Date

October 25, 2019

Primary Completion Date

March 23, 2020

Study Completion Date

March 23, 2020

Conditions
Urologic Neoplasms
Trial Locations (1)

606-8507

Research Site, Kyoto

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY